Comparison of pyrotinib or lapatinib with chemotherapy for patients with HER2 positive breast cancer after first-line treatment failure: a retrospective study
CONCLUSION: After the failure of first-line trastuzumab-containing treatment, combination of pyrotinib with chemotherapy has more significant short-term efficacy in HER-2 positive breast cancer patients than lapatinib combined with chemotherapy, especially in patients with brain metastasis.PMID:34650767 | PMC:PMC8507037
Source: American Journal of Translational Research - Category: Research Authors: Huihui Yang Wei Wang Source Type: research
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Herceptin | Neurology | Research | Study